38 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
with Lewy bodies
DNP
the FDA’s Division of Neurology Products
DSCSA
Drug Supply Chain Security Act
EEA
European Economic Area
EEG
electroencephalogram … and pharmaceutical supply chain, an important decision that may lead to appears to be leading to further and more aggressive efforts by states
8-K/A
EX-99.2
fnjbfq
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
g0apg5zz4rttf2
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
424B3
ycm00riubvt
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
sj6l8334
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
kqqfszla21 blw7rvd9m
10 May 23
Registration of securities issued in business combination transactions
9:56pm
DEFA14A
ob5goa v2g
16 Dec 22
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
tg3mjb
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
DEFA14A
EX-99.1
0c3oo9n rq0a7qm50
5 Dec 22
Additional proxy soliciting materials
9:59pm
8-K
EX-99.1
sqj7s cvs
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
8-K
EX-99.1
23tpn4po19b39
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
aipf2xad3492yaef6
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
9xdi yyzn
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
7d4b48s y6r6
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
9oudg9a2tfzwgrhtj
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm